Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018140974) PASSIVE ANTIBODY DEPENDENT CELL-MEDIATED ACTIVATION
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for treating a subject infected with a pathogen encoding an Fc-binding protein, the composition comprising an

immunological polypeptide comprising a domain that binds an FcyR on an immune effector cell and a non-overlapping domain that binds the pathogen- encoded Fc binding protein.

2. The pharmaceutical composition of claim 1, wherein the immune effector cell is a B cell, a natural killer (NK) cell, a monocyte, a macrophage, a neutrophil or granulocyte, T cell or a dendritic cell.

3. The pharmaceutical composition of claim 1, wherein the pathogen encoding an Fc-binding protein is herpes simplex virus (HSV), cytomegalovirus, or Varicella zoster virus (VZV).

4. The pharmaceutical composition of claim 3, wherein the pathogen-encoded Fc binding protein comprises a herpesvirus glycoprotein E (gE) or a

cytomegalovirus 68kDa-glycoprotein (gp68).

5. The pharmaceutical composition of claim 1, wherein the immunological polypeptide comprising a domain that binds an FcyR on an immune effector cell is an Fc fragment of an IgG antibody.

6. A method of treating a subject infected with a pathogen encoding an Fc- binding protein comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1.

7. The method of claim 6, wherein the immunological polypeptide comprising a domain that binds an FcyR on an immune effector cell is an Fc fragment of an IgG antibody.

8. A pharmaceutical composition for preventing neurologic damage in a subject with HSV1 infection, the composition comprising an immunological polypeptide comprising a domain that binds an FcyR on an immune effector cell and a non-overlapping domain that binds a herpes simplex virus-encoded Fc binding protein.

9. A method of for preventing neurologic damage in a subject with HSV1

infection comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 8.

10. A pharmaceutical composition for preventing death in a subject with HSVl infection, the composition comprising an immunological polypeptide comprising a domain that binds an FcyR on an immune effector cell and a non-overlapping domain that binds a herpes simplex virus-encoded Fc binding protein.

11. A method of for preventing death in a subj ect with HSVl infection comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 10.

12. A pharmaceutical composition for treating cancer in a subject undergoing oncolytic viral therapy, the composition comprising an immunological polypeptide comprising a domain that binds an FcyR on an immune effector cell and a non-overlapping domain that binds a Fc binding protein on a target cell.

13. A method for treating cancer in a subject undergoing oncolytic viral therapy comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 12.

14. A pharmaceutical composition for enhancing oncolytic viral therapy in a subj ect, the composition comprising an polypeptide comprising a region that binds to a binds a Fc binding protein on a target cell but does not comprise a region that binds to a Fc gamma receptor (FcyR).

15. A method enhancing oncolytic viral therapy in a subject comprising

administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 14.

16. The method of claim 15, wherein the pharmaceutical composition is

administered prior to treatment with an oncolytic viral therapeutic agent.

17. A method of reducing inflammation in a subj ect receiving anti-cancer therapy comprising:

(a) administering a therapeutically effective amount of a polypeptide comprising a region that binds to a Fc binding protein but does not comprise a region that binds to a Fc gamma receptor (FcyR); and

(b) administering an anti-cancer therapy comprising a monoclonal

antibody drug.

18. The method of claim 17 wherein the monoclonal antibody drug is rituximab, tocilizumab, tositumomab, trastuzumab bevacizumab, brentuximab vedotin, cetuximab, daratumumab, ipilimumab, ofatumumab, panitumumab, alemtuzumab or pembrolizumab.

19. The method of claim 17, wherein the pharmaceutical composition is

administered prior to treatment with the monoclonal antibody drug.

20. The method of claim 17, wherein the pharmaceutical composition comprises an immunological polypeptide comprising a domain that binds an FcyR on an immune effector cell that is an Fc fragment of an IgG antibody.

21. A method increasing efficiency of generating dendritic cells or macrophages from PBMC or monocytes comprising culturing PBMC or monocytes in plates pre-coated with protein A or protein G, or with polymerized protein A or protein G.